Hong Kong Adventist Hospital – Stubbs Road has introduced targeted radionuclide therapy using the radioactive isotope Lutetium-177 (Lu-177), providing an advanced treatment option for some patients with advanced or metastatic cancer.
How the Treatment Works
In Lu-177 radionuclide therapy, a radioactive medicinal product is linked to a molecule that recognizes specific receptors or markers on tumor cells, allowing the medicine to accumulate more in tumor tissue.
Lu-177 PSMA treatment is one form of Lu-177 radionuclide therapy. It uses a radiolabelled drug to target and destroy tumor cells that express prostate specific membrane antigen (PSMA), while aiming to minimize the impact on surrounding healthy tissues.
Potential Benefits
- Delivers radiation more directly to tumor sites
- Short radiation range helps reduce exposure to nearby normal organs
- May offer an additional option when other treatments are no longer effective or suitable
Patients Who May Be Considered (subject to specialist assessment)
- Patients with certain advanced or metastatic malignancies
- Tumors showing suitable targets for this treatment on imaging or other tests (such as PSMA)
- Patients who have received, or are unsuitable for, standard therapies but still require further disease control
- Patients whose overall condition and major organ function, particularly kidney function and bone marrow reserve, are suitable for radionuclide therapy
Suitability for Lu-177 radionuclide therapy and the detailed treatment plan will be determined by our multidisciplinary team based on each patient’s clinical condition and investigation results. For enquiries or to arrange a specialist consultation, please contact our Oncology Clinic.
Treatment Room
